Viveve, Inc., the wholly owned subsidiary of Viveve Medical, Inc., is a women’s health company headquartered in Englewood, Colorado.
The Viveve® System is indicated for treatment of the vaginal introitus, after vaginal childbirth, to improve sexual function in Australia, Brazil, Canada, Chile, Colombia, Costa Rica, Hong Kong, Japan, Malaysia, Mexico, Panama, Philippines, Singapore, and United Arab Emirates.
The Viveve System is indicated for treatment of vaginal laxity in Bahrain, EU, Iceland, Korea, Kuwait, Lebanon, Liechtenstein, Norway, Qatar, Switzerland, Turkey, and Ukraine.
The Viveve System is indicated for use in General Surgical procedures for electrocoagulation and hemostasis in Thailand, Taiwan, and the United States.
The Viveve System is contraindicated for use in patients with either an Implantable Pacemaker or an Automatic Implantable Cardioverter/Defibrillator (AICD), or any other implantable electrical device, as they may be adversely affected by radio-frequency (RF) fields or current.
The Viveve System is not available for sale in countries not listed above.
Location: United States, Illinois, Chicago
Phone: +1 720-696-8100
Total raised: $6.76M
Founded date: 2016
Investors 3
| Date | Name | Website |
| - | 5AM Ventur... | 5amventure... |
| - | Avoro Capi... | avorocapit... |
| - | CRG | crglp.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.08.2019 | - | $6.76M | - |
Mentions in press and media 18
| Date | Title | Description | Source |
| 05.02.2022 | Viveve Medical : Schedule filed to report acquisition of ben... | SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exc... | marketscre... |
| 18.01.2022 | Viveve Medical : Schedule filed to report acquisition of ben... | SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Excha... | marketscre... |
| 05.01.2022 | Viveve Medical : Initial registration statement for securiti... | As filed with the Securities and Exchange Commission onJanuary 4, 2022 Registration No. 333- UNITE... | marketscre... |
| 14.12.2021 | Viveve Medical : Announces Completion of Full Enrollment in ... | Viveve Announces Completion of Full Enrollment in Pivotal U.S. PURSUIT Trial for Stress Urinary Inco... | marketscre... |
| 14.12.2021 | Viveve Medical : Current report filing | false 0000879682 | marketscre... |
| 12.11.2021 | Quarterly report pursuant to Section 13 or 15(d) | 0000879682 VIVE ... | marketscre... |
| 28.10.2021 | Viveve Announces Issuance of New Device and Methods Patent i... | Viveve Announces Issuance of New Device and Methods Patent in U.S Download as PDFOctober 28, 2021 ... | marketscre... |
| 23.09.2021 | Viveve Medical : Announces Issuance of New Method Patent for... | Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia Downloa... | marketscre... |
| 03.08.2021 | Viveve Medical : Announces Continued Expansion of IP Portfol... | Viveve Announces Continued Expansion of IP Portfolio with Issuance of Canadian Patent Download as P... | marketscre... |
| 08.07.2021 | Viveve Medical : Announces New Category III CPT Code for its... | Viveve Announces New Category III CPT Code for its Stress Urinary Incontinence Procedure Download a... | marketscre... |
Show more